Epigenomics AG

WHO'M
ai
Digital Profiler. Simply click the AI button
CUSIP

N/A
SEDOL

N/A
CIK

N/A

www.epigenomics.com
LEI: 549300X1C4U862NDLN97
New: Infographics X-Lab
FIGI: BBG000BLCRX1
ECX

Epigenomics AG
GICS: - · Sector: - · Sub-Sector: -
AI
PROFILER
NAME
Epigenomics AG
ISIN
DE000A37FT41
TICKER
ECX
MIC
XFRA
REUTERS
ECX.DE
BLOOMBERG
ECX GR
F&G: 27
21.999,40 DAX · 24,88 Vola-Index · 93.143,46 BTC · 1,13717 EURUSD
FOR INVESTORS
FOR TRADERS
Securities Trading Warrants
EQS Newswire is a major provider of regulatory and corporate news. It mainly serves companies, investors and media worldwide. Through its services, EQS Newswire enables efficient and secure communication between companies and their stakeholders. Its main services include the distribution of ad hoc announcements, corporate news and the publication of financial reports that meet strict international standards.
Tue, 30.04.2024

Epigenomics AG: Executive Board member Jens Ravens leaves the Company on April 30, 2024 Berlin (Germany), April 30, 2024 - Jens Ravens, Executive Board member of Epigenomics AG (Frankfurt General Standard: ECX, the “Company”), leaves the Executive Board of the Company with effect as of April 30, 2024 due to the successful transfer of nearly all a...
Tue, 30.04.2024

Epigenomics AG: Executive Board member Jens Ravens leaves the Company on April 30, 2024 Berlin (Germany), April 30, 2024 - Jens Ravens, Executive Board member of Epigenomics AG (Frankfurt General Standard: ECX, the “Company”), leaves the Executive Board of the Company with effect as of April 30, 2024 due to the successful transfer of nearly all a...
Thu, 14.03.2024

Epigenomics AG publishes financial results for fiscal year 2023 Berlin (Germany), March 14, 2024 – Epigenomics AG (FSE: ECX, the “Company”) today reported financial results (according to HGB) for fiscal year 2023. OPERATIONAL DEVELOPMENTS Due to the lack of necessary financing for the further development of the Epi proColon “Next-Gen” test and t...
Thu, 15.02.2024

Epigenomics AG: Jochen Hummel appointed to the Supervisory Board to replace Heikki Lanckriet Berlin, February 15, 2024 - Epigenomics AG (Frankfurt General Standard: ECX; the “Company”), a holding company focusing on investments in the field of minimally invasive blood tests for cancer detection, announces that upon application of the Executive Bo...
Wed, 31.01.2024

Epigenomics AG: Supervisory Board of Epigenomics AG appoints Hansjörg Plaggemars as member of the Executive Board Berlin, January 31, 2024 - Epigenomics AG (Frankfurt General Standard: ECX; the "Company"), a holding company focusing on investments in the field of minimally invasive blood tests for cancer detection, announces that the Supervisory ...
Fri, 26.01.2024

Epigenomics AG: Resignation of Supervisory Board Member Dr Heikki Lanckriet (PhD) Berlin, Germany, January 26, 2024 – Dr Heikki Lanckriet (PhD) has informed the competent bodies of Epigenomics AG (Frankfurt General Standard: ECX, the “Company”) that he resigned as a member of the Company's Supervisory Board with effect as of 22 February 2024. The...
We are different
OPEN FINANCIAL
DATA & KNOWLEDGE HUB
We make the difference
Information on product placements

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S